LOS ANGELES--(BUSINESS WIRE)--Jun 12, 2024-- Treating prostate cancer with immunotherapy is currently difficult to do. But preliminary results from a first in-human phase 1 trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope ®, one of the largest cancer research and treatment organizations in the United States, showed that patients with advanced prostate cancer had minimal side effects with the cellular immunotherapy and had promising therapeutic activity, according to a study published today in Nature Medicine . This press release features multimedia.
View the full release here: https://www.businesswire.com/news/home/20240612751963/en/ Saul Priceman, Ph.
D., City of Hope associate professor, Department of Hematology & Hematopoietic Cell Transplantation, and Tanya Dorff, M.D.
, City of Hope section chief, Genitourinary Disease Program, and their teams worked together on the phase 1 clinical trial using a City of Hope-developed CAR T cell therapy for prostate cancer. (Photo: Business Wire) The trial treated 14 prostate stem cell antigen (PSCA)-positive patients who had metastatic castration resistant prostate cancer (mCRPC), which had spread beyond the prostate and no longer responded to hormone treatment, using CAR T cell therapy. More than 34,000 men with this type of prostate cancer die each year in the United States.
Saul Priceman , Ph.D., City of Hope associate professor, Department of Hematology & Hematopoietic Cell Tran.
